4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
4DMT Provides Company Update and Anticipated Development Milestones for 2026
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely [Yahoo! Finance]
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop [Seeking Alpha]
4D Molecular Therapeutics (NASDAQ:FDMT) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $26.00 price target on the stock.